Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT05326243 · RECRUITING

Trial details

NCT number: NCT05326243
Sponsor: Pell Bio-Med Technology Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Primary Mediastinal Large B Cell Lymphoma Large B-cell Lymphoma Follicular Lymphoma Grade 3A Follicular Lymphoma Grade 3B

Start date: 2022-05-31
Primary completion: 2026-12-31
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.